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Abstract
Background:  Studies on recurrent tuberculosis (TB), TB molecular epidemiology and drug
susceptibility testing rely on the analysis of one Mycobacterium tuberculosis isolate from a single
sputum sample collected at different disease episodes. This scheme rests on the postulate that a
culture of one sputum sample is homogeneous and representative of the total bacillary population
in a patient.
Methods: We systematically analysed several pre-treatment isolates from each of 199 smear-
positive male adult inmates admitted to a prison TB hospital by standard IS6110  DNA
fingerprinting, followed by PCR typing based on multiple loci containing variable number of tandem
repeats (VNTRs) on a subset of isolates. Drug susceptibility testing (DST) was performed on all
isolates for isoniazid, rifampicin, streptomycin and ethambutol.
Results: We found mixed infection in 26 (13.1%) cases. In contrast, analysis of a single pre-
treatment isolate per patient would have led to missed mixed infections in all or 14 of these 26
cases by using only standard DNA fingerprinting or the PCR multilocus-based method, respectively.
Differences in DST among isolates from the same patient were observed in 10 cases, of which 6
were from patients with mixed infection.
Conclusion: These results suggest that the actual heterogeneity of the bacillary population in
patients, especially in high TB incidence settings, may be frequently underestimated using current
analytical schemes. These findings have therefore important implications for correct interpretation
and evaluation of molecular epidemiology data and in treatment evaluations.
Background
Tuberculosis (TB) has been traditionally assumed to result
from a single infection with a single Mycobacterium tuber-
culosis  strain, and this infection is thought to confer
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immunity to additional infections. Therefore, a recurrence
of disease has been most often considered to be caused by
endogenous reactivation of the strain that caused the orig-
inal infection (relapse). Consequently, almost all current
analytical schemes of clinical or research relevance are still
based on examination of single isolates of given disease
episodes, with implicit assumption that this isolate is rep-
resentative of an homogeneous bacillary population.
This model of homogeneous infection has been revised by
several studies using strain typing methods, which have
demonstrated the occurrence of infection with clonally
distinct strains, especially in high-incidence settings [1-3].
Both human immunodeficiency virus (HIV)-negative and
HIV-positive individuals can be infected with more than
one strain during a given disease episode (mixed infec-
tion), or re-infected by a second M. tuberculosis strain dur-
ing a recurrent episode (exogenous re-infection). Such
findings have important implications for control pro-
grams, vaccine development, evaluation of treatment reg-
imens [4], and for epidemiological interpretation [3,5].
However, these studies of re-infection and mixed infec-
tion have so far been conducted by analysing the geno-
types of the isolate from one sputum specimen from the
initial and recurrent episodes or from one given episode,
respectively [6-8]. Such approaches discount the old pos-
tulate that bacilli sequestered at different pulmonary
infection sites are not necessarily released in the sample
provided. Therefore, analysis of a single isolate might
underestimate the actual heterogeneity of the bacillary
population in the host. Conversely, the consequences of
clonal heterogeneity on the representativeness of a single
isolate have remained unknown hitherto.
Here, we have prospectively evaluated both the frequency
of mixed infections and the clonal heterogeneity among
clinical isolates from the same patient by analysing at least
two pre-treatment isolates from each of 199 TB patients
from a prison TB hospital in Georgia, consecutively
enrolled over a period of three years. These isolates were
analysed by using standard IS6110-restriction fragment
length polymorphism (RFLP) genotyping as a first-line
screening, followed by typing based on PCR amplification
of 15 different loci containing mycobacterial interspersed
repetitive unit-variable number of tandem repeats (MIRU-
VNTRs) for independent confirmation of simultaneous
presence of multiple strains. The implications of the
results for current analytical schemes of drug susceptibil-
ity testing (DST) and for evaluation of the contribution of
re-infection to the epidemiology and pathogenesis of this
disease are discussed.
Methods
Study population
All consecutive newly registered adult inmates (≥15 years
of age) with pulmonary TB admitted to a prison TB hospi-
tal near Tbilisi, Georgia from February 2001 to March
2004 were enrolled. All the TB patients included in our
study were held in different detention centres and were
only referred to the TB prison hospital after they were
diagnosed with TB. TB history of study patients was
according to the World Health Organization (WHO)
guidelines [9]. TB notification rates in the general popula-
tion during the study period was on average 117.3 cases
per 100 000 population (2001–2003) [10]. The HIV
infection rate in the Georgian population is <0.2% [11]
and 1% among hospitalised TB patients [12]. Demo-
graphic data, including sex, age as well as date of diagno-
sis, clinical diagnosis, and treatment history, were
obtained by review of medical and laboratory records. The
study was approved by the Ministry of Justice of Georgia.
Samples and cultures
Three sputum samples were collected under strict supervi-
sion at the TB hospital from each of the patients within
one week before the initiation of anti-TB treatment, which
were collected as part of the routine patient investigation.
Each sputum sample from all the patients studied was
decontaminated by the modified Petroff's method [13]
and cultured on Löwenstein-Jensen (L-J) medium at the
National TB Reference Laboratory in Tbilisi, Georgia. The
cultures were incubated at 37°C and read weekly for
growth for a maximum period of 8 weeks. Identification
of the primary isolates was done by classical methods.
Drug-susceptibility testing
DST was done on all M. tuberculosis isolates at the Prince
Leopold Institute of Tropical Medicine (ITM) in Antwerp,
Belgium by the proportion method on L-J medium con-
taining 0.2 µg/ml isoniazid (INH), 40 µg/ml rifampicin
(RIF), 4 µg/ml streptomycin (SM) and 2 µg/ml ethambu-
tol (EMB) [14].
DNA extraction
DNA was extracted either by boiling bacterial suspensions
for 5 min (MIRU-VNTR) or as previously described (RFLP
and MIRU-VNTR) [15].
DNA fingerprinting
DNA fingerprinting of all M. tuberculosis isolates was per-
formed by the IS6110-RFLP method [15]. Typing of iso-
lates was done blinded i.e. only ITM culture numbers were
used to identify isolates during DNA fingerprinting.
Patient identities were only revealed when comparing the
patterns (BioNumerics, version 3.0; Applied Maths, Sint-
Martens-Latem, Belgium). DNA fingerprinting patterns
from samples collected over the same period of time wereRespiratory Research 2006, 7:99 http://respiratory-research.com/content/7/1/99
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reviewed to detect potential laboratory cross-contamina-
tions or errors.
Secondary typing by MIRU-VNTR was performed on iso-
lates from 30 patients with differences in their IS6110-
hybridisation patterns and on isolates from another 30
patients with identical IS6110-RFLP patterns (controls),
using 15 MIRU-VNTR loci selected from a wider set of loci
based on their variability in unrelated isolates and stabil-
ity in clonally related isolates [16-21]. These loci have
been found to be more discriminative and better for use
in molecular epidemiology studies of TB (Supply et al., in
preparation) than the 12 previously described loci [20],
and they will be therefore proposed for standardisation.
The number of repeats in the 15 target loci was deter-
mined after multiplex PCR with fluorescently labelled
primers against regions flanking the repetitive sequences,
electrophoretic separation and sizing of the PCR products
using an ABI 3730 XL sequencer [2,19,22]. Specific pre-
cautions were taken to avoid and control cross contami-
nation.
Steps taken to minimise laboratory error
To avoid swapping of sputum samples between patients,
containers were pre-labelled with patient identities before
sample collection. To minimise laboratory cross-contam-
ination during decontamination and culture of samples,
work was done in laminar flow cabinets, and only a lim-
ited number of specimens were processed at a time. In
addition, study samples were received in batches both in
Georgia and Belgium and were processed separately from
all other samples received by the laboratory.
To minimise the risk of cross contamination during sam-
ple preparation for MIRU-VNTR typing, sample prepara-
tion for PCR, and the addition of DNA was done in a
laminar flow cabinet. The H37Rv M. tuberculosis strain and
water were included in each experiment as positive and
negative controls, respectively. Reagent contamination
could not be detected as all the negative controls were
negative on amplification, and the correct number of
repeats and no double alleles were detected from the pos-
itive controls.
Statistical methods
Analysis of variance (ANOVA) was used to compare con-
tinuous variables and the χ2 test was used for comparisons
of proportions between test groups. The analyses were
conducted using the Statistical Package for Social Sciences
(SPSS version 14.0). A p value < 0.05 was considered sig-
nificant.
Results
Mycobacterial cultures and patient characteristics
Of the 385 eligible subjects, 186 patients were excluded
because: only one sample was culture-positive for M.
tuberculosis or yielded a good subculture upon receipt in
Antwerp (102), only one isolate had IS6110-RFLP results
(60), isolates were not available for IS6110-RFLP finger-
printing after shipment (23), and probable laboratory
error (1). The conclusion on the latter case was based on
the fact that one of the isolates from the latter patient had
identical DNA fingerprinting patterns with an isolate from
another patient processed on the same day. Thus, 199
patients with more than one M. tuberculosis isolate with
IS6110-RFLP results were included in the analysis (Figure
1). All the study subjects were male, and the median age
of the 198 patients with available age was 30 years (range,
20 to 63 years). Of these, 134 patients were new cases and
the remaining 65 patients were retreatment cases. There
was no statistically significant difference in the age (p =
0.301) or retreatment types (p = 0.485) of patients that
were excluded from the study and those that were
included.
Detection of mixed infections
IS6110-RFLP screening
All sets of M. tuberculosis pre-treatment isolates available
from 199 patients were genotyped by IS6110-RFLP. The
number of IS6110  copies among these isolates ranged
from 5 to 18 (median, 11 bands). Isolates from 169
patients showed identical patterns within each set, sug-
gesting infection by a single strain. In contrast, isolates
from 12 patients (patients 19–30) showed minor differ-
ences in IS6110-RFLP patterns within their respective sets
ranging from 1 to 3 bands indicative of heterogeneous
subpopulations, whereas isolates from 18 patients
showed major differences of more than 3 bands sugges-
tive of infection by multiple strains (mixed infection).
Among the latter, isolates from 7 patients (patients 1–7)
showed very distinct IS6110-RFLP patterns. Of the
remaining 11 patients (patients 8–18), at least one isolate
appeared to be a mixture of two different M. tuberculosis
strains, as evidenced by possession of multiple overlap-
ping bands compared to the other isolate(s) from the
same patient (see Additional file 1, Table 2).
MIRU-VNTR typing
To study the observed heterogeneity further, all pre-treat-
ment isolates from 30 patients with major (patients 1–18)
and minor (patients 19–30) IS6110-RFLP differences were
typed by MIRU-VNTR using 15 independent loci. In addi-
tion, all pre-treatment isolates from 30 patients with iden-
tical IS6110-RFLP patterns, presumably infected with a
single strain, were also typed by MIRU-VNTR as controls.
These control isolates were selected to cover the spectrum
of IS6110 profiles among the different IS6110-RFLP clus-Respiratory Research 2006, 7:99 http://respiratory-research.com/content/7/1/99
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ters and unique isolates found among the 169 sets of iso-
lates with conserved fingerprints within a set.
Consistently, respective isolates from the 18 patients with
major IS6110 band differences were all found to have very
distinct MIRU-VNTR profiles as well, corroborating the
conclusion of mixed infection. More detailed analyses of
the MIRU-VNTR results of these 18 patients showed that
for some of them, different strains could be detected only
in different sputum specimens, whereas for other patients
the different strains were found to be simultaneously
present within one sample. For example, isolates from
two of these patients (patients 4 and 5) displayed MIRU-
VNTR profiles differing by 10 and 14 loci respectively, and
all showed a single allele per locus. This observation pro-
vides evidence for the presence of a single strain per sam-
ple, but different from the strain from another specimen
of the respective patient. Isolates from 14 other patients
from this group (patients 1–3, 6–8, 11–18) showed a
combination of single alleles differing among the respec-
tive pre-treatment samples, and double alleles detected in
at least three loci (see Additional file 1, Table 2). One of
the two alleles in these loci systematically corresponded to
the single allele detected in the same locus of the other
isolate(s) from the same patient, or the same double alle-
les were detected in both isolates. This finding indicates
the simultaneous presence of at least two distinct strains,
which can be detected in one or more sputa. Furthermore,
even triple alleles were reproducibly amplified from three
loci of both isolates from patient 10, suggesting the simul-
taneous presence of three distinct strains. This conclusion
was corroborated by the detection of double alleles at
three other loci of one of the isolates, none of which was
detected in the same locus of the other isolate from that
patient. A similar phenomenon was also noticed for both
isolates of patient 9, but without detection of any triple
allele.
Similarly, the respective isolates from 5 of 12 patients with
minor IS6110 band differences showed different and/or
double alleles in at least three MIRU-VNTR loci, indicat-
ing mixed infections. Interestingly, mixed infections as
Schematic diagram showing the grouping of patients according to culture results and subsequent IS6110-RFLP and MIRU- VNTR typing Figure 1
Schematic diagram showing the grouping of patients according to culture results and subsequent IS6110-RFLP and MIRU-
VNTR typing.
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Table 1: Patient and drug susceptibility results of pre-treatment isolates from patients with variant DNA fingerprinting patterns
Patient no. Retreatment type Age (years) Isolate no. Drug susceptibility testing
INH RIF SM EMB
Patients infected with multiple (mixed) M. tuberculosis strains
Patients with incomplete DST results
2N e w  c a s e2 3 a N T N T N T N T
bS S S S
Patients with only pan-susceptible isolates
6 New case 22 a + b + c S S S S
7 New case 36 a + b + c S S S S
8N e w  c a s e3 8 a  +  b S S S S
12 New case 41 a + b + c S S S S
17 New case 57 a + c S S S S
18 New case 34 a + c S S S S
19 New case 24 b + c S S S S
30 New case NA a + b + c S S S S
Patients with identical drug resistant isolates
5N e w  c a s e2 6 a  +  b R S S S
11 New case 29 a + b S S R S
10 New case 27 a + b + c S S R S
24 New case 58 b + c S S R S
33 New case 23 a + b S S R S
29 Return after default 29 a + b S S R S
22 Previously received non-official TB treatment 27 a + b S S R S
16 New case 29 a + b R S R S
31 Relapse case 38 a + b R R R R
3 New case 44 a + b+ c R R R R
32 Failure case 21 b + c R R R R
Patients with different drug resistant isolates
14 New case 41 b S S S S
c R SS S
13 New case 51 a R S S S
cR S R S
4N e w  c a s e3 6 a S S S S
bS S R S
1 Previously received non-official TB treatment 50 a S S R S
b R SR S
c R SR S
15 Return after default 29 a R S S S
bR S R S
cR S R S
9N e w  c a s e2 4 a R S R S
c R? SR S
Patients infected with clonal subpopulations of the same M. tuberculosis strain
Patients with only pan-susceptible isolates
25 New case 25 b + c S S S S
20 Relapse case 27 a + b + c S S S S
Patients with identical drug resistant isolates
21 New case 43 b + c S S R S
26 New case 37 b + c S S R S
27 New case 27 a + b S S R S
28 New case 40 a + b + c S S R S
23 New case 32 a + b + c R S R S
Definitions of abbreviations: INH = isoniazid; RIF = rifampicin; SM = streptomycin; EMB = ethambutol, S = Susceptible; R = Resistant; R? = 
borderline resistance; NT = not tested; a = first pretreatment sputum; b = second pretreatment sputum; c = third pretreatment sputum; NA = not 
available.Respiratory Research 2006, 7:99 http://respiratory-research.com/content/7/1/99
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defined on the same MIRU-VNTR basis were also revealed
among 3 of the 30 patients whose isolates had identical
IS6110  fingerprints. Detection of mixed infections by
MIRU-VNTR typing among patients with isolates showing
identical IS6110-RFLP patterns is not surprising because
the former method includes an amplification step and a
more sensitive, fluorescence-based, detection system.
Identical MIRU-VNTR profiles were obtained among the
isolates from the 7 remaining patients with minor IS6110
band differences (mostly one band, at most 3 bands), and
from the 27 remaining control sets with conserved IS6110
fingerprints. In keeping with previous studies [2,23,24],
the former group was conservatively assigned to IS6110
clonal variants from one original infecting strain and were
thus defined as clonal subpopulations, while the latter
group corresponded to cases of infection by a single strain,
as defined by both typing methods used.
Based on IS6110-RFLP data on all isolates and MIRU-
VNTR data on isolates from 60 patients we found infec-
tion with a single M. tuberculosis strain either homogene-
ous or with some clonal subpopulation in 173 (86.9%) of
199 patients, and mixed infection with two or three dis-
tinct strains in 26 (13.1%) patients. Crucially, using the
above rules for identification of mixed infections (detec-
tion of double alleles in multiple loci), analysis of a single
pre-treatment isolate per patient would have led to missed
mixed infection in 14 of these cases using MIRU-VNTR
typing. Analysis of a single pre-treatment isolate per
patient would have even led to missed mixed infection in
all cases using standard IS6110-RFLP, as no evidence of
strain mixture could be detected in single patterns.
Twenty-one of the 26 patients with mixed infection were
new TB cases, 1 was a treatment failure case, 3 returned
after default while 1 had previously received unofficial TB
treatment (Table 1). The distribution of the treatment his-
tory of TB among these cases was not significantly differ-
Table 2: Results of 33 patients with multiple pre-treatment isolates showing variant DNA fingerprinting patterns
Patient no. No. of bands different by IS6110-RFLP No. of loci with different/double alleles Interpretation
1 >3 10 Mixed infection
2 >3 10 Mixed infection
3 >3 12 Mixed infection
4 >3 14 Mixed infection
5 >3 10 Mixed infection
6 >3 11 Mixed infection
7 >3 13 Mixed infection
8 >3 8 Mixed infection
9 >3 11 Mixed infection
10 >3 15 Mixed infection
11 >3 10 Mixed infection
12 >3 12 Mixed infection
13 >3 8 Mixed infection
14 >3 7 Mixed infection
15 >3 9 Mixed infection
16 >3 10 Mixed infection
17 >3 9 Mixed infection
18 >3 12 Mixed infection
19 1 5 Mixed infection
29 1 4 Mixed infection
30 3 7 Mixed infection
31 0 2 Mixed infection
32 0 7 Mixed infection
33 0 10 Mixed infection
22 1 4 Mixed infection
24 1 13 Mixed infection
20 1 0 Identical/subpopulations
21 1 0 Identical/subpopulations
23 1 0 Identical/subpopulations
25 1 0 Identical/subpopulations
26 1 0 Identical/subpopulations
27 1 0 Identical/subpopulations
28 3 0 Identical/subpopulations
Patients are arranged according to the interpretationRespiratory Research 2006, 7:99 http://respiratory-research.com/content/7/1/99
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ent from the distribution among those infected with a
single homogeneous or heterogeneous strain (χ2, p =
0.117).
Drug susceptibility testing
Phenotypic DST classified 80 of 199 patients as having
been infected with pan-susceptible isolates and 20
patients with multi-drug resistant (MDR) isolates. The
remaining 99 patients were infected with isolates that
were resistant to at least one drug, but not MDR.
From 25 out of 26 mixed infection cases with known DST
results for all isolates, 8 patients were infected with only
pan-susceptible strains, while the other cases showed
resistance in at least one of the isolate. Out of these, clear
differences in resistance patterns among isolates from the
same patient were observed only in 5 cases (patients 1, 4,
13, 14, 15, Table 1). In another case (patient 9) however,
one isolate showed a clear resistance to INH whereas a
borderline result was obtained in the other. Isolates from
patients 1 and 14 differed in their susceptibility to INH,
which was confirmed by sequencing of the katG and inhA
genes (data not shown). The resistant isolate for patient 9
was confirmed by sequencing i.e. presence of a novel T→C
(in contrast to the previously reported T→A or G) muta-
tion at position -8 of the inhA gene [24]. Interestingly, a
mixture of both a wild type (T) and the novel mutation
(C) was obtained at the same position for the isolate with
a borderline result, thereby corroborating our MIRU-
VNTR findings. Patient 9 and 14 were new cases, while
patient 1 had previously received unofficial anti-TB treat-
ment. Difference in SM resistance was observed in the
remaining 3 patients (4, 13, 15), but this was not investi-
gated further.
In contrast to the above mixed infection cases with iso-
lates showing different DST patterns, it is remarkable to
note that the remaining 11 patients were infected with
two or three different M. tuberculosis strains that showed
exactly the same DST pattern: 1 mono-INH-resistant, 6
mono-SM-resistant, 2 INH + SM-resistant and 3 MDR.
Eight of these patients were classified as new cases (Table
1).
Finally, among the 7 patients with clonal subpopulations,
none showed differences in DST among their respective
sets of isolates whereas among the patients with geneti-
cally homogeneous bacterial populations, one retreat-
ment and three new cases showed a difference in SM
among the isolates (data not shown).
Discussion
This report simultaneously assessed the validity of two
interdependent postulates on which standard analytical
schemes rely: (i) that a TB patient can only be infected
with a single homogeneous M. tuberculosis strain at any
given time, and (ii) that an isolate from a single sputum
specimen is representative of the total bacillary popula-
tion in a patient. Therefore, we systematically compared
the genetic relatedness of M. tuberculosis isolates from
multiple sputum samples collected prior to the initiation
of anti-TB therapy from each of 199 smear-positive
inmates admitted to a prison TB hospital. By using two
independent genotyping methods to differentiate strains,
we detected infection with two or even three distinct M.
tuberculosis  strains in 13.1% of the samples analysed.
There was no significant difference in the proportion of
retreatment cases between the excluded and included
patients.
The mixed infection rate observed in this prison popula-
tion can not be extrapolated to the general population
because of overcrowding and higher incidence of TB in the
prisons compared to the general population (5,995/100
000 vs. 155/100 000 population, respectively) [26]. How-
ever, we believe that the so called "cheating" (i.e. prisoners
attempt to submit sputa mixed with that of other prison-
ers suspected of having smear-positive TB, so that they can
be diagnosed with TB and transferred to the prison TB
hospital with better living conditions than in other deten-
tion centres) had a low influence on our estimation of this
phenomenon, if any, due to the strict and active surveil-
lance by an aware staff at the sputum collection step
inside the TB hospital. Likewise, laboratory cross-contam-
ination is an unlikely explanation for the high frequency
of mixed infection detected because of the specific precau-
tions taken.
The use of IS6110-RFLP-typing as an initial screening
method may have led to some underestimation of mixed
infection because this method has inherent limitations to
detect mixed infections within a single isolate since vari-
ous bands in a given profile can represent one or more
strains. Moreover, it remains unclear to what extent low
ratios of one of the strains present in a mixture are
reflected in low-intensity bands [27] or not detected at all.
The latter is evidenced by the detection of mixed infec-
tions by MIRU-VNTR among 3 (10%) of 30 patients with
isolates that showed identical IS6110-RFLP patterns but
double alleles in multiple loci within one isolate by
MIRU-VNTR. By extrapolation, this suggests that up to 14
(7.0%) mixed infections might have been additionally
detected among the other 139 patients with isolates that
had identical IS6110-RFLP patterns if they were also tested
by MIRU-VNTR. There was no statistically significant dif-
ference in retreatment type between new and previously
treated cases among the patients whose isolates were only
typed by IS6110-RFLP and those whose isolates were addi-
tionally typed by MIRU-VNTR (χ2, p = 0.15). Finally,
some mixed infections could have remained undetectedRespiratory Research 2006, 7:99 http://respiratory-research.com/content/7/1/99
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by MIRU-VNTR typing itself although this PCR-based
method is able to detect ratios of a given strain as low as
1:99 [28].
Detection of genetically distinct strains among multiple
pre-treatment sputum samples, as well as within a single
sputum specimen might reflect separate lesions in the
lungs containing different M. tuberculosis strains and
opening simultaneously or consecutively as also sug-
gested from a previous study [29]. Regardless of the expla-
nation, it is crucial to note that if only the first pre-
treatment sample was analysed by standard IS6110 finger-
printing or by MIRU-VNTR typing, none or only about
half of the mixed infection cases detected by analysis of
multiple pre-treatment samples (14 cases vs. 26 cases)
would have been identified. These observations imply
that analysis of a single isolate, especially in high inci-
dence settings may underestimate the actual heterogeneity
of the bacillary population in the host.
It is relevant to observe that the 13.1% of mixed infections
detected in this prison population is relatively close to the
frequency of 19% recently reported in the study of Warren
et al. in a general population of a setting with an incidence
1000/100 000 population [3]. Although the two values
are not directly comparable as this latter evaluation was
limited to the detection of patients simultaneously
infected with strains of both the Beijing and non-Beijing
lineages, we predict that their value is likely an underesti-
mation as only single isolates per patient were analysed in
that case. Similarly, previous studies in high incidence set-
tings might have overestimated the contribution of rein-
fection vs. relapse due to undetected initial mixed
infection [7,29]. Our observations imply that for specific
research studies analyses of several isolates from different
sputum samples at each disease episode (before and after
treatment), especially in high TB incidence settings might
be helpful in distinguishing true reinfection vs. relapse
and/or mixed infection, preferably using a PCR-based typ-
ing method like MIRU-VNTR.
From the 26 proven mixed infection cases in our study,
30% harboured only pan-susceptible strains, whereas
70% showed any resistance in at least one of the isolates.
In only 6 cases was mixed infection reflected in a variant
DST profile. Remarkably, the remaining patients were
infected with two or three strains seemingly showing
identical resistance profiles. Although most of these
patients were new cases according to WHO definitions
[9], we can not completely exclude the possibility that
they might have taken TB drugs for less than one month,
and therefore both strains might have acquired resistance
as a result of the same drug pressure. On the other hand,
independent infection with two or three strains showing
exactly the same resistance profile for each of so many
patients is very doubtful as well, even in a setting with a
high rate of drug-resistant TB. Most probably, such fre-
quent observations of identical resistance profiles among
respective isolates from these mixed infections reflect the
systematic presence of both a susceptible and a resistant
strain in the corresponding specimens. This systematic
duality was evidenced by the systematic detection of dou-
ble alleles in the MIRU-VNTR patterns in the isolates from
all these cases but one. In such conditions, the simultane-
ous growth of a (more) resistant strain will mask that of
susceptible (or partly resistant) strains in DST assays
either completely or partly resulting in either resistant iso-
lates or isolates with borderline results (patient 9). In such
situations, culturing and DST of single pre-treatment spu-
tum had generally no predictable adverse consequences
for the appropriateness of the treatment regimen of the
respective patients.
As mentioned above, variant DST profiles were detected as
a result of mixed infections in only 6 (3.0%) of the 199
patients. This finding lends support to previous reports
that initial mixed infections may actually be responsible
for changes in DST patterns in isolates of some patients
[29-31].
In general, our findings suggest that single-isolate analyses
can be used for routine DST in most settings, except for
some high drug resistant-TB-prevalent settings. However,
for specific research studies like treatment evaluation and
clinical trials, testing multiple isolates from different spu-
tum samples at each disease episode could help in deter-
mining the respective contribution of mixed infection and
reinfection versus relapse with gradual development of
drug resistance, especially by PCR-based typing methods
such as MIRU-VNTR.
Although the high rates of mixed infection in this prison
setting can not be extrapolated to the general population
with a lower risk of TB transmission, these findings none-
theless indicate that an initial infection is unable to pro-
vide protection against a subsequent infection in these
populations, which have implications for the develop-
ment and trials of new vaccines [3]. Because higher rates
of mixed infection imply possible higher rates of super
infection, the protective effect of an initial infection
against a subsequent infection may be even lower than
expected. This parameter needs to be taken into account
in the development of new prophylactic approaches.
Conclusion
This study has demonstrated that different pre-treatment
sputum samples from a patient can harbour distinct M.
tuberculosis strains. In addition, the study has shown the
occurrence of varying DST patterns among multiple pre-
treatment isolates, which might indicate mixed infectionRespiratory Research 2006, 7:99 http://respiratory-research.com/content/7/1/99
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or ongoing acquisition of drug resistance. Our findings
are important for the correct interpretation of molecular
epidemiology data in follow-up studies in high incidence
settings and in treatment evaluations.
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